From the bench to the boardroom, women at Ascidian are redefining what’s possible in RNA medicine.
As we approach International Women’s Day, we celebrate their leadership, resilience, and impact —today and every day.
#IWD #GiveToGain #WomenInBiotech
On #RareDiseaseDay, learn how Ascidian is working to rewrite the story of #StargardtDisease. See and hear🎶 how our RNA exon editors work ⬇️
Then explore our Phase 1/2 STELLAR clinical trial and our STARPATH prescreening study: 🔗 stellarstargardttrial.com
Happy Lunar New Year from #TeamAscidian 🐎🔥
The Year of the Fire Horse brings energy, courage, and forward momentum — the same spirit powering how we redefine what’s possible in RNA therapeutics.
Here’s to igniting progress and turning bold science into real impact for patients.
#RNAExonEditing
This #RareDiseaseMonth, we’re celebrating accessibility that sparks joy.
Bricks for the Blind adapts LEGO instructions so visually impaired builders can create independently — showing that vision loss doesn’t have to mean losing what you love.
Read more: bit.ly/3Z7CViT
#StargardtDisease
#ICYMI, earlier this month Ascidian and Forge Biologics announced a manufacturing partnership to advance ACDN-01, our lead RNA exon editing candidate for #StargardtDisease.
Check out this BioProcess International article to learn more:
tinyurl.com/y6c434mv
#TeamAscidian will be travelling next week for #JPM26, engaging with peers and partners as we continue to advance #RNAExonEditing programs for Stargardt and other genetic diseases. See you in SF! ✈️
Today Ascidian and Forge Biologics unveiled our manufacturing partnership. Through the collaboration, Forge’s FUEL™ platform and cGMP services will produce AAV for ACDN-01, securing the clinical supply needed to advance into late-stage studies.
Learn more: 🔗 bit.ly/49vnvdf
Heading to the Jefferies Global Healthcare Conference and London Life Science Week? Connect with Ascidian’s Daniel Rosan and Jon Blanc as we advance RNA exon editing therapeutics to transform Stargardt and other genetic diseases: outreach@ascidian-tx.com ✈️🌍💂♂️
As #BlindnessAwarenessMonth wraps up, check out Bradford Manning’s must-see master class on #StargardtDisease, which launched last year. We’re grateful to have been part of it: bit.ly/3yB9trX. #ShareYourVision
✨This #BlindnessAwarenessMonth, we’re grateful for voices that catalyze change✨
In 2023, Two Blind Brothers visited Ascidian through our FFB Vision Walk sponsorship, sharing their #StargardtDisease story.
Their words still remind us why we do what we do & why every step with this community matters.
✨Walking strong in Boston✨ This past weekend #TeamAscidian joined @FightBlindness.bsky.social
for the Boston Vision Walk—our final stop of 2025.
From coast to coast we’ve raised awareness & built community, & we’re excited to lace up again in 2026! 👟🦮
#VisionWalkStrong #BioSky #ShareYourVision
Attending the Alliance for Regenerative Medicine’s 2025 Cell & Gene Meeting on the Mesa? 🌵 🧬
If so, be sure to check out our Ascidian company presentation TODAY:
📅 Oct 6 | 4:30 PM
📍 FLW Ballroom G | Arizona Biltmore
🧷 bit.ly/46P3ooU
@alliancerm.bsky.social
#CGMesa25 #RNAExonEditing
Join us & The Carroll Center for the Blind this #WorldSightDay for the “Journey Through Vision Loss” event.
Hear from @fightblindness.bsky.social, mental health experts & advocates, plus updates on our #RNAExonEditing candidate ACDN-01 & the #STELLAR trial in #StargardtDisease.
🧷 bit.ly/42bSmsd
Dan Rosan, MBA, CFO & CBO of Ascidian to participate in CFO Corner panel on September 17, 2025, in Boston, MA.
What’s top of mind for biotech CFOs in 2025 and beyond?
Our Chief Financial & Business Officer Daniel Rosan joins Informa’s ‘CFO Corner’ to talk biotech trends, deals, and what’s next for leadership in 2025 and beyond.
Don’t miss it: bit.ly/4lN8p6K
📍 Sept 17 | 9:45 AM
📌 Sheraton Boston
Excited to share that Ascidian is a 2025 Prix Galien USA nominee for Best Start-Up.
Thank you to The Galien Foundation for the recognition, and to our #TeamAscidian colleagues for turning bold ideas into breakthroughs. Congrats to this year’s nominees!
#PrixGallienUSA #RNAExonEditing #BioSky
We’re thrilled to welcome Dr. Murray A. Abramson as Chief Development Officer & announce our new Ophthalmology Clinical Advisory Board guiding ACDN-01 for #StargardtDisease. Big things ahead!
🔗 ascidian-tx.com/press-releas...
#RNAExonEditing #TeamAscidian #Biosky
Smart alliances. Strategic alignment. Real talk.
Ascidian’s Dan Rosan joins industry leaders for a candid panel at the Goodwin + PJT Partners session on M&A & partnering in today’s market. Don’t miss it. 🔗https://bit.ly/43AT6Z5
📍 June 18 | 12–2:30 PM
📌 Goodwin’s Boston office
#BIO2025 #Biosky
At #CGTP2025 tomorrow, Ascidian’s John Kerwin joins other biotech leaders and gene-editing expert Dr. Kiran Musunuru to discuss the latest advancements in gene editing technologies and their transformative potential for patients. Don’t miss it. #RNAExonEditing #GeneTherapy
🎸 Silvi Rouskin brings rock-star creativity to RNA science—with Harvard rigor to match.
A one-of-a-kind mind pushing RNA structural research forward with cutting edge techniques ⬇️
#TeamAscidian #RNAExonEditing #Biosky
🧬 A pioneer in RNA biology, Roy Parker has spent his career unraveling how life works — one molecule at a time. He’s shaped our understanding of how RNA is regulated, degraded, and stored — and why it matters. ⬇️ #RNAExonEditing #TeamAscidian #Biosky
🎓 From journalism major to expert in alternative splicing and RNA-binding proteins: a registration mix-up sparked Brenton Graveley’s path to becoming a leader in RNA biology. ⬇️ #RNAExonEditing #TeamAscidian #Biosky
We’re kicking off our SAB spotlight series with RNA-
pioneer Mariano A. Garcia-Blanco. A trans-splicing trailblazer whose love for science runs generations deep ⬇️
#RNAExonEditing #TeamAscidian #Biosky
Introducing Ascidian’s Scientific Advisory Board – trailblazers in #RNA biology and gene expression who’ve made groundbreaking contributions in the field of RNA splicing and to research, mentoring and education. Join us in welcoming them 👏 #Biosky ascidian-tx.com/wp-content/u...
Our Bluesky debut! 🚀 This weekend, we joined leading retinal disease research experts at the RD Fund Investing in Cures Summit, where our CSO Robert Bell shared insights on #RNAExonEditing & #StargardtDisease. Grateful for @fightblindness.bsky.social’s leadership in this space! #biosky
